Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations

Prevention of viral escape and increased coverage against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal antibodies (mAbs) targeting multiple sites of vulnerability on the coronavirus spike glycoprotein. Here we identify several potent...

Full description

Saved in:
Bibliographic Details
Published inNature immunology Vol. 22; no. 12; pp. 1503 - 1514
Main Authors Dussupt, Vincent, Sankhala, Rajeshwer S., Mendez-Rivera, Letzibeth, Townsley, Samantha M., Schmidt, Fabian, Wieczorek, Lindsay, Lal, Kerri G., Donofrio, Gina C., Tran, Ursula, Jackson, Nathaniel D., Zaky, Weam I., Zemil, Michelle, Tritsch, Sarah R., Chen, Wei-Hung, Martinez, Elizabeth J., Ahmed, Aslaa, Choe, Misook, Chang, William C., Hajduczki, Agnes, Jian, Ningbo, Peterson, Caroline E., Rees, Phyllis A., Rutkowska, Magdalena, Slike, Bonnie M., Selverian, Christopher N., Swafford, Isabella, Teng, I-Ting, Thomas, Paul V., Zhou, Tongqing, Smith, Clayton J., Currier, Jeffrey R., Kwong, Peter D., Rolland, Morgane, Davidson, Edgar, Doranz, Benjamin J., Mores, Christopher N., Hatziioannou, Theodora, Reiley, William W., Bieniasz, Paul D., Paquin-Proulx, Dominic, Gromowski, Gregory D., Polonis, Victoria R., Michael, Nelson L., Modjarrad, Kayvon, Joyce, M. Gordon, Krebs, Shelly J.
Format Journal Article
LanguageEnglish
Published New York Nature Publishing Group US 01.12.2021
Nature Publishing Group
Nature Research, Springer Nature
Subjects
Online AccessGet full text

Cover

Loading…